Theravance Biopharma Inc. (NASDAQ:TBPH) traded down 0.4% during mid-day trading on Friday . The stock traded as low as $22.90 and last traded at $22.90, with a volume of 85,365 shares. The stock had previously closed at $23.00.

Several equities research analysts recently issued reports on the company. Leerink Swann reiterated a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Bank of America Corp. cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Guggenheim assumed coverage on Theravance Biopharma in a report on Monday, June 20th. They issued a “buy” rating and a $30.00 price objective on the stock. Zacks Investment Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Finally, TheStreet upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Monday, March 21st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and an average price target of $24.33.

The stock’s market capitalization is $1.11 billion. The company has a 50-day moving average price of $22.57 and a 200 day moving average price of $19.01.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.14. The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $18.69 million. Analysts expect that Theravance Biopharma Inc. will post ($4.24) EPS for the current year.

An institutional investor recently raised its position in Theravance Biopharma stock. OppenheimerFunds Inc. boosted its position in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 at the end of the most recent reporting period.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.